Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥ 10 positive axillary lymph nodes

Oncology

Volumn 55, Issue 6, 1998, Pages 508-512

  Fountzilas, George ^a   Nicolaides, Costas ^b   Aravantinos, Gerasimos ^c   Skarlos, Dimosthenis ^c   Kosmidis, Paris ^e   Papakostas, Pavlos ^d   Stathopoulos, George P ^d   Kontostolis, Emmanouil ^b   Bafaloukos, Dimitrios ^e   Pavlidis, Nicholas ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c AGII ANARGIRI CANCER HOSPITAL   (Greece)

^d HIPPOKRATION HOSPITAL   (Greece)

^e METAXA CANCER HOSPITAL   (Greece)

Author keywords

Adjuvant chemotherapy; Breast cancer; Epirubicin

Indexed keywords

EPIRUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; FEASIBILITY STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; NAUSEA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED;

EID: 0031723795     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011903     Document Type: Article

References (25)

1. Jones SE, Moon TE, Bonadonna G, Valagussa P, Riukin S, Buzdar A, Montaque, Powles T: Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 1987; 10:387-395.
2. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP: Management and survival of female breast cancer: Results of a national survey by the American college of surgeons. Cancer 1980;45:2917-2924.
3. Moon TE, Jones SE, Bonadonna G, Valagussa P, Powles T, Buzdar A, Montague E: Development and use of a natural history data base (NHDB) of breast cancer studies. Am J Clin Oncol 1987;10:396-403.
4. Rivkin S, Glucksberg H, Foulkes M: Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: A comparison of CMFVP versus L-Pam (Southwest Oncology Group Study); in Jones SE, Salmon SE (eds): Adjuvant Therapy of Cancer Part. IV. Orlando, Grune & Stratton, 1984, pp 209-216.
5. Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Zambetti M, Veronesi U: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 1985;5:95-115.
6. Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U: Adjuvant CMF in breast cancer: Comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1983;1:2-10.
7. Buzdar AU, Kau S-W, Hortobagi GN, Ames FC, Holmes FA, Fraschini G, Hug V, Theriault RL, McNeese MD, Singletary SE: Clinical course of patients with breast cancer with ten or more positive nodes who treated with doxorubicin containing adjuvant therapy. Cancer 1992;69:448-452.
8. Buzzoni R, Bonadonna G, Valagnssa P, Zambeni M: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 1991;9:2134-2140.
9. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-1288.
10. Wood WC, Budman DR, Korzum AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Ballow AC, Frei E III, Henderson IC: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330: 1253-1259.
11. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70: 163-169.
12. Fountzilas G, Skarlos D, Giannakakis T, Athanasiades A, Bafaloukos D, Kalogera-Fountzila A, Bamia C, Pavlidis N, Kosmidis P: Intensive chemotherapy with high-dose epirubicin every two weeks and prophylactic administration of filgastrim in advanced breast cancer. Eur J Cancer 1994;30A:965-969.
13. Fountzilas G, Athanassiades A, Giannakakis T, Briasoulis E, Bafaloukos D, Kalogera-Fountzila A, Onienaoum A, Kalofonos H, Pectasides D, Andreopoulou E, Kosmidis P, Pavlidis N, Skarlos D: A randomized study of epirubicin monotherapy every 4 or every 2 weeks in advanced breast cancer. Ann Oncol 1997;8:1-8.
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
15. Jaiyesimi IA, Buzdar AU: Adjuvant chemotherapy in high-risk breast cancer patients with ten or more positive lymph nodes. Am J Clin Oncol 1992;15:180-183.
16. Abeloff MD: High-dose adjuvant chemotherapy for high-risk breast cancer. Recent Results Cancer Res 1993;127:177-183.
17. Gianni AM, Siena S, Di Nicola M, Orefice S, Cusumano F, Salvadori B, Luini A, Greco M, Zucali R, Rilke F, Zambetti M, Valagussa P, Bonadonna G: Efficacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes. Five-year results. J Clin Oncol 1997;15:2312-2321.
18. Fountzilas G, Polichronis A, Katsohis K, Gennatas K, Toussis D, Skarlos D, Kosmidis P, Vassilaros S, Semoglou C, Giannakakis T, Fahantidis E, Klouvas G, Potamianou A, Tsavaris N, Konstantaras C, Makrantonakis P, Kolotas C, Hainoglou D, Mylonakis N, Pavlidis N: Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node positive breast cancer patients. A Hellenic Cooperative Oncology Group Study. Oncology 1996;53:137-146.
19. Hudis C, Seidman A, Baselga J, Raptis G, Lebwohi D, Gilewski T, Currie V, Moynahan ME, Sklarin N, Fennelly D, Uhlenhopp M, Riedel E, Yao T-J, Norton L: Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four of more axillary nodes. Semin Oncol 1995;22(suppl 1):18-23.
20. Riccio L, Hudis C, Seidman A, Raptis G, Crown J, Baselga J, Fennelly D, Lebwohl D, Theodoulou M, Gilewske T, Skalrin N, Surbone A, Currie V, Moynahan M, Reidel E, Tao Y, Yia TJ, Norton L: Long-term distant disease-free survival for two pilot studies of dose-dense sequential adjuvant chemotherapy in women with resected breast cancer and > 3 positive lymph nodes. Proc Am Soc Clin Oncol 1997;16:145A.
21. Crump M, Goss PE, Prince M, Girouard C: Outcome of extensive evaluation before adjuvant therapy in whomen with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 1996;14:66-69.
22. Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, Peto R, Baum M, Fisher B, Host H, Lythgoe J, Ribeiro G, Scheurlen H: Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994;12:447-453.
23. Early Breast Cancer Trialists' Collaborative Group: Effects of radiotherapy and surgery in early breast cancer. N Engl J Med 1995;333: 1444-1455.
24. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K for the Danish Breast Cancer Cooperative Group 82b Trial: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 1997;337:949-955.
25. Sledge GW, Antman KH: Progress in chemotherapy for metastatic breast cancer. Semin Oncol 1992;19:317-332.